ClinicalTrials.gg
CompletedNCT00753506Updated Feb 28, 2012Results posted

Artemisinin to Reduce The Symptoms of Schizophrenia

An interventional study of Artemisinin and Identical looking placebo capsule in Schizophrenia and Schizoaffective Disorder, sponsored by Sheppard Pratt Health System. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-02-28.

Sponsored by Sheppard Pratt Health System · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,466 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.

Enrollment
657th of 1,320
66 · median 66
Started
2008
with 67 others
No phase
480 of 1,466
72 open now
Registered
426th of 1,466
by date

Among the 1,466 studies in Schizophrenia with a site in United States, this one is the 657th largest by enrollment of the 1,320 interventional ones that give a count, is one of 68 that started in 2008, is one of 480 with no phase, and was the 426th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

148 of the 1,466 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,466 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the antimalarial compound artemisinin when used in addition to standard antipsychotic medications.

Read the detailed description

The aims of the current study are:

  1. To evaluate the efficacy and side effects of artemisinin as an add-on compound for patients with schizophrenia who have residual psychotic symptoms of at least moderate severity.
  2. To evaluate the effect of artemisinin on cognitive impairments and associated functional skills.
  3. To investigate whether treatment with artemisinin produces a significant effect on the levels of antibodies to Toxoplasma.
  4. To examine whether changes in cognitive impairment or psychiatric symptoms are correlated with changes in antibodies to Toxoplasma before and during the treatment with artemisinin.
03

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65 years old.
  • Capacity for written .
  • Primary Axis I diagnosis () of schizophrenia, any type, OR schizoaffective disorder (APA, 1994).
  • Currently an outpatient at the time of enrollment.
  • Residual psychotic symptoms which are at least moderately severe as evidenced by one or more Positive and Negative Syndrome Scale (PANSS) positive symptom scores, and/or PANSS negative symptom scores of 4 or more; OR a total PANSS score of 50 or more, containing at least three positive or negative items with scores of 3 or more at screening.
  • Conformance to Patient Outcome Research Team (PORT) Treatment Recommendation #5, Maintenance Antipsychotic Medication Dose (Lehman et al., 2004).
  • Receiving antipsychotic medication for at least 8 weeks prior to starting the study with no medication changes within the previous 21 days.
  • Participants must be proficient in English.

Exclusion criteria

Exclusion Criteria

  • Diagnosis of mental retardation.
  • History of IV drug use.
  • Any serious medical condition that affects brain or cognitive functioning (e.g., epilepsy, serious head injury, brain tumor or other neurological disorder).
  • infection or other immunodeficiency condition.
  • Primary diagnosis of substance abuse or dependence according to criteria within the last three months.
  • Participated in any drug trial in the past 30 days.
  • Pregnancy or planning to become pregnant during the study period.
  • Any or unstable medical disorder as determined by the investigators that would preclude study participation, including congestive heart failure, abnormal liver function or disease, renal failure, and any diagnosis of cancer undergoing active treatment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (actual)

Study arms

  • Active comparator
    Artemisinin

    100 mg artemisinin capsule

    Dietary Supplement: Artemisinin

  • Placebo comparator
    Placebo

    Identical looking placebo capsule

    Dietary Supplement: Identical looking placebo capsule

Interventions

  • Dietary supplementArtemisinin

    100 mg of artemisinin twice per day for 10 weeks

  • Dietary supplementIdentical looking placebo capsule

    Identical looking placebo twice per day for 10 weeks

06

What researchers measure

Primary outcomes

  1. Change in Positive and Negative Syndrome Scale (PANSS) Score From the Beginning to the End of the Double-blind Treatment Phase Weeks 2-12

    The Positive and Negative Syndrome Scale (PANSS) measures psychiatric symptomatology, especially related to psychosis. The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The severity of each symptom is rated on a scale ranging from 1 (minimal) to 7 (extreme); higher scores indicate increased symptomatology. Total PANSS scores include scores from all categories and range from 30 to 210 units on a scale. PANSS positive symptom scores and negative symptom scores each range from 7 to 49 units on a scale.

    Time frame: 10 weeks (weeks 2 & 12)

Secondary outcomes

  1. Change in Cognitive Functioning as Measured by the Repeatable Battery for the Assessment of Neuropsychological Status and Change in Functional Performance as Measured by the UCSD Performance-based Skills Assessment.

    Time frame: 10 weeks (weeks 2 & 12)

07

Results

Posted Feb 20, 2012

Participant flow

We enrolled n=66 participants drawn from the Sheppard Pratt Health System and from rehabilitation and treatment programs in Central Maryland. Dates of recruitment 8/08-1/10.

Participant flow — Overall Study
MilestoneArtemisininPlacebo
Started3333
Completed2631
Not completed72
Withdrew: Withdrawal by subject41
Withdrew: Lost to follow-up20
Withdrew: Other reason11

Outcome measures

PrimaryChange in Positive and Negative Syndrome Scale (PANSS) Score From the Beginning to the End of the Double-blind Treatment Phase Weeks 2-12

The Positive and Negative Syndrome Scale (PANSS) measures psychiatric symptomatology, especially related to psychosis. The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The severity of each symptom is rated on a scale ranging from 1 (minimal) to 7 (extreme); higher scores indicate increased symptomatology. Total PANSS scores include scores from all categories and range from 30 to 210 units on a scale. PANSS positive symptom scores and negative symptom scores each range from 7 to 49 units on a scale.

Time frame:
10 weeks (weeks 2 & 12)
Reported as:
Mean · units on a scale
Change in Positive and Negative Syndrome Scale (PANSS) Score From the Beginning to the End of the Double-blind Treatment Phase Weeks 2-12
units on a scaleArtemisininPlacebo
Week 2 PANSS total symptom score64 ± 8.7468.13 ± 9.07
Week 12 PANSS total symptom score61.42 ± 10.5366.32 ± 9.45
Week 2 PANSS positive score15.42 ± 4.1816.26 ± 3.96
Week 12 PANSS positive score14.92 ± 5.1116.35 ± 5.35
Week 2 PANSS negative score19.08 ± 3.1219.77 ± 3.48
Week 12 PANSS negative score18.69 ± 3.6919.03 ± 3.67
Week 2 PANSS general score29.5 ± 5.3232.10 ± 6.18
Week 12 PANSS general score27.81 ± 4.7830.94 ± 4.84
Statistical analysis
  • Artemisinin vs Placebo · ANOVA · p = >0.10 · F: 1.59
SecondaryChange in Cognitive Functioning as Measured by the Repeatable Battery for the Assessment of Neuropsychological Status and Change in Functional Performance as Measured by the UCSD Performance-based Skills Assessment.
Time frame:
10 weeks (weeks 2 & 12)

Results for this outcome have not been posted.

Adverse events

Collected over 8/08-1/10. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Artemisinin—3/33 (9.1%)0/26 (0%)
Placebo—3/33 (9.1%)0/31 (0%)
Most frequent serious events
Most frequent serious events
EventArtemisininPlacebo
Schizophrenia exacerbationPsychiatric disorders2/332/33
Arm fracture requiring hospitalizationMusculoskeletal and connective tissue disorders0/331/33
Atypical chest painCardiac disorders1/330/33

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ArtemisininPlaceboTotal
<=18 years000
Between 18 and 65 years333366
>=65 years000
Age Continuous
Age Continuous(years)ArtemisininPlaceboTotal
Mean45.4 ± 9.049.2 ± 9.247.3 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)ArtemisininPlaceboTotal
Female131528
Male201838
Region of Enrollment
Region of Enrollment(participants)ArtemisininPlaceboTotal
United States333366
08

Study locations

1 site
  • Sheppard Pratt Health System
    Towson, Maryland 21204, United States
09

References and documents

Publications

  • Dickerson F, Stallings C, Vaughan C, Origoni A, Goga J, Khushalani S, Yolken R. Artemisinin reduces the level of antibodies to gliadin in schizophrenia. Schizophr Res. 2011 Jul;129(2-3):196-200. doi: 10.1016/j.schres.2011.04.010. Epub 2011 May 5. PubMed 21546216 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2008
First posted
Sep 16, 2008
Start
Aug 2008
Primary completionActual
May 2010
CompletionActual
May 2010
Results first posted
Feb 20, 2012
Last update
Feb 28, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00753506
Lead sponsor
Sheppard Pratt Health System
Collaborators
Stanley Medical Research Institute
Responsible party
Faith Dickerson, PhD, MPH (Head, Stanley Research Program, Sheppard Pratt Health System) — Principal investigator
First posted
Sep 16, 2008
Start date
Aug 2008
Primary completion
May 2010
Completion
May 2010
Results posted
Feb 20, 2012
Last update
Feb 28, 2012

Study contacts

Faith B Dickerson, PhD, MPH
principal investigator · Stanley Research Program at Sheppard Pratt

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Artemisinin

Start the discussion